STEFAN LEMPERLE, M.D., PH.D., MBA
PRESIDENT & CEO
Dr. Stefan Lemperle founded AscentX Medical, Inc. in April 2008 and has since served as the Company's President and CEO. From January 2007 to April 2009, Dr. Lemperle was the President and CEO of Clinicon Corporation, a privately held medical technology company that develops, manufactures and markets fractional CO2 lasers and diamond laser scalpels.
In April 1999, Dr. Lemperle co-founded Artes Medical Inc., a NASDAQ-listed medical technology company, which developed and secured FDA approval for the first and only permanent injectable wrinkle filler (ArteFill®) (acquired by Suneva Medical, Inc. in 2009). He served as Vice-Chairman of the Board of Directors and President & Chief Executive Officer of Artes Medical Inc. from April 1999 to December 2006.
In 1996, Dr. Lemperle co-founded MacroPore Inc. (now Cytori Therapeutics Inc., NASDAQ: CYTX), a medical technology company focused on the design, manufacture and distribution of bio-degradable bone fixation and regeneration devices for craniofacial and spine surgery. He served as Vice-Chairman of MacroPore, Inc.'s Board of Directors, Executive Vice President R&D, and Chief Scientific Officer between 1996 - 2000.
In August 2014, Dr. Lemperle graduated at the top of his class from Pepperdine University's President & Key Executive (PKE) MBA Program at the Graziadio School of Business and Management.
From July 1994 to October 1996, Dr. Lemperle was a post-doctorate research fellow at the University of California, San Diego, Division of Plastic Surgery, fully sponsored by the Deutsche Forschungsgemeinschaft (DFG) (German Research Society).
In 1992, Dr. Lemperle earned his M.D. degree and completed his 'Dr. med.' degree with Magna Cum Laude (or High Honors), equivalent to a 'Ph.D. degree in Medicine', as certified by U.S. Center for Educational Documentation (CED), from the Johann Wolfgang von Goethe University Frankfurt/Main, Germany, where he was also trained in general surgery between 1992-1994.
Between 1985-1997, Dr. Lemperle was a regular team member of INTERPLAST Germany, where he participated in yearly reconstructive surgery missions to third world countries throughout the world.
Dr. Lemperle is author/co-author of various scientific publications in the fields of Liver Transplantation, Bone Regeneration, Aesthetic Surgery, GERD and SUI. Dr. Lemperle holds various patents in medical technology. In 2005, Dr. Lemperle was a San Diego finalist for the Ernst & Young Entrepreneur of the Year® Awards.
WILLIAM GREENE, BS Business Administration (Accounting)
SENIOR VP FINANCE
Prior to becoming our Chief Financial Officer in December 2015, since November 2001 through December 2015, Mr. Greene has served in the positions of Chief Financial Officer, Vice President of Investor Relations, as well as CFO consultant in providing his wide variety of industry clients with SEC compliance, stock registration, equity financing services and business services.
His broad business industry experience includes high technology, manufacturing, distribution, marketing, service and physician provider businesses. From June 2006 through February 2008, Mr. Greene served as Chief Financial Officer for Surge Global Energy, Inc., a public company with interests in the Canadian oil sands market, and provided SEC compliance, SB-2 stock registrations, financing road shows, assisted in $18 million equity and debt raises, a $17 million acquisition, a $20 million asset sale and investor relations management.
From February 2004 through August 2004, Mr. Greene served as a Vice President of Entech Environmental Technologies, Inc., where his primary duties were investor relations, SEC compliance and equity financing support.
From November 1999 through November 2001, Mr. Greene was an associate at Resources Connection, the consulting business group previously affiliated with Deloitte, where his team leader responsibilities included improving and resolving client’s financial reporting, accounting and financial modeling challenges.
From 1996-1998 Mr. Greene served as Cost of Sales, Overhead Analyst at Hewlett Packard.
After commencing his career as an auditor with Arthur Andersen & Company in 1980, Mr. Greene then served as Controller for a variety of high tech manufacturing and marketing companies.
Mr. Greene obtained his Bachelor of Science degree in Business Administration, with a concentration in accounting, from California State University, Dominguez Hills in 1980.
RUSSELL ANDERSON, M.S. PharmE, MBA
EXEC VP ENGINEERING & PRODUCT DEVELOPMENT, CTO
Since October 2010, Mr. Russell Anderson has served as President and Board member of Biostratus Corporation, a biomedical development and consulting firm. From January 2009 to October 2010, Mr. Anderson served as Program Director and Vice President of Product Development and Engineering at Lithera, Inc., a San Diego based Pharmaceutical and Biomedical Technology Company. From January 2004 to November 2008, Mr. Anderson served as the Vice President of Manufacturing & Engineering and Vice President of Product Development & Engineering at Artes Medical Inc., a publicly held medical technology company that developed ArteFill®, the first and only permanent injectable wrinkle filler to gain FDA approval. From 2002 until recently, Mr. Anderson was the President and a Principal Engineer of Anderson Biomedical Consulting and his corporate clients included Johnson & Johnson (Ethicon), Amgen, Genentech, Novartis, Sandoz, Roche, NuVasive, Boston Scientific, Collagen Corporation, Target Therapeutics, Vascular Innovations, Alliance Pharmaceuticals, and Stemedica amongst others.
Prior to founding Anderson Biomedical Consulting, he held management positions at Mentor Corporation, Medtronic, Keravision, Cohesion Technologies, and Novare Surgical. In 2009, Russell finished at the top of his class while earning a Master’s of Science degree in PharmME from the Stevens Institute of Technology. He also holds additional graduate certifications in Biologics and Biopharmaceutical Processing, as well as Pharmaceutical Manufacturing Management. In 2000, Mr. Anderson received a Master’s Degree with honors in Business Administration from California State University, Hayward, with concentrations in Production & Operations Management, Technology and Innovation Management, and International Business Management. Mr. Anderson also received a BSEnvE/BSME from California Polytechnic State University at San Luis Obispo. Russell has authored or co-authored dozens of domestic and international issued and pending biomedical patents, and he has also co-authored multiple papers on tissue treatment technologies that have been published in peer reviewed journals.
SHEPARD BENTLEY, RAC
SENIOR VP REGULATORY AFFAIRS & QUALITY ASSURANCE
Shep Bentley, RAC, is a regulatory affairs expert with proven experience at achieving domestic and international market approvals for innovative devices applying equally innovative approaches to regulators.
His ability to pursue the least burdensome approach by the use of unique expressions of risk has met with success at the FDA and outside the U.S. With 32 years in the medical device industry and a wealth of knowledge and understanding of the letter and intent of federal regulations, he has built a solid reputation within the U.S. Department of Health & Human Services. Within the past ten years, Shep has extended his experience to the markets of the Australia, Brazil, Canada, China and the European Union. He maintains competitive relationships for his regulatory efforts. Within the past year, Shep has been featured as a keynote speaker and regulatory expert in conferences and symposia in the United States and Europe. His passion is to enable the best in medical technology to reach the public in the shortest time.
Shep's past clients as a regulatory consultant for device and drug regulatory strategies in U.S., Europe, Canada, Brazil, China, and Australia include numerous firms such as Abbott Labs, Alcon, Amgen, Baxter, Cardinal Health, Covidien, Edwards Lifesciences, Johnson & Johnson, Medtronic, St. Jude, and Valeant.
Shep holds the rank of U.S. Marine Corps Lieutenant Colonel (ret.) and served in both Iraq wars.
He earned his Bachelor of Arts in Philology (International Literature) and advanced his studies at the Johannes Gutenberg University in Mainz/Germany. His professional affiliations include RAPS and TOPRA
LARRY BRAGA, Senior Vice President
Mr. Larry Braga served as the Principal of BioWerks Consulting, a Biotechnology, Pharmaceutical and Medical Device consulting firm from December 2008 to December 2010. From June 2004 to November 2008, Mr. Braga served as the Vice President of Global Manufacturing Operations for Artes Medical Inc., a publicly held medical technology company that developed ArteFill, the first and only FDA approved permanent injectable wrinkle filler. From 2000 to 2004, he served as the Senior Director of Global Manufacturing Operations for Anosys, Inc. (Rhone-Poulenc Rorer spin-off), a French founded vaccine company focused on the treatment of Non-Small Cell Lung Carcinoma and Melanoma, autologous cell therapies and targeted tumor peptides. Prior to Anosys, Mr. Braga served in various clinical and commercial manufacturing management roles at Cohesion Technologies and Collagen Corporation. Mr. Braga began his Biotechnology career at Genentech in 1986, supporting one of the first commercial recombinant products, Human Growth Hormone (Protopin). In 1985, Mr. Braga earned his Bachelor of Science degree in Biological Science from California State University, Hayward, with a Medical Technology Focus.
PROF. GOTTFRIED LEMPERLE, M.D., PH.D.
CHIEF MEDICAL OFFICER
Professor Gottfried Lemperle joined AscentX Medical, Inc. as a co-founder in October 2008 and currently serves as the Company's Chief Medical Officer. Dr. Lemperle has been a Voluntary Clinical Professor at the University of California, San Diego School of Medicine, Department of Surgery, Division of Plastic Surgery since 1998. In April, 1999, Professor Lemperle co-founded Artes Medical Inc., a publicly held medical technology company based on his invention of the PMMA microsphere platform technology leading to the first and only FDA approved permanent injectable wrinkle filler (ArteFill®) in 2006. He served as Chief Scientific Officer of Artes Medical Inc. from August 1999 to May 2006. Prior to Artes Medical, Professor Lemperle spent over 30 years as Professor & Head of the Division of Plastic & Reconstructive Surgery at the University of Frankfurt/Main, Germany.
Professor Lemperle was awarded M.D. and Ph.D. degrees in Immunology and General and Plastic Surgery from Frankfurt University. He has authored more than 270 original publications in the fields of Plastic Surgery, GERD and SUI.
In 1997 Prof. Lemperle received the Cross of Merit 1st Class (Bundesverdienstkreuz 1. Klasse) from the President of the Republic of Germany for his achievements as founder of INTERPLAST Germany, a non-profit organization providing reconstructive surgery services in third world countries around the world. In 2010 Prof. Lemperle received the Dieffenbach-Medal as a German Lifetime Award for his contributions to the field of Plastic & Reconstructive Surgery.